Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals

Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal implant; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - Alimera Sciences/EyePoint Pharmaceuticals; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/EyePoint Pharmaceuticals; YUTIQ

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; EyePoint Pharmaceuticals; Hospital for Special Surgery; Johns Hopkins University; pSivida Inc; Specialised Therapeutics Australia
  • Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Uveitis

Highest Development Phases

  • Marketed Diabetic macular oedema; Uveitis
  • Phase II Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration
  • Phase I Osteoarthritis

Most Recent Events

  • 17 Sep 2019 Alimera Sciences expands the distribution agreement with Horus Pharma for Diabetic macular oedema and Uveitis in Belgium, Netherlands, Luxembourg
  • 05 Aug 2019 Registered for Diabetic macular oedema in Australia (Intravitreous, Implant)
  • 30 Jul 2019 Updated efficacy and adverse events data from a phase III trial in Uveitis released by EyePoint Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top